A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

Biogen

Status: Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Study type: Observational

Funder types: Industry

Identifiers

NCT06127095

2023-A01349-36 (Other Identifier)

FR-TYS-12186

Details and patient eligibility

About

The primary objective of the study is to understand what the added value of natalizumab (Tysabri®) treatment is from a participant's perspective at a given time, based on a one-shot survey. The secondary objectives of the study also aim to characterize the participant's decision-making process to get the treatment; the burden of treatment, characterization of the study population, assessment of the quality of life (QoL), and fatigue dimension.

Enrollment: 474 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants diagnosed with RRMS and followed by a neurologist in France.

Exclusion criteria

• Lack of literacy

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Trial design

474 participants in 1 patient group

Participants with RRMS

Description:

Participants who receive natalizumab intravenously (IV) or subcutaneously (SC) or ocrelizumab, or ofatumumab, as per the standard local prescribing procedures will be enrolled to collect data. Participants will complete an online one-shot questionnaire combining closed and open-ended questions.